<DOC>
	<DOCNO>NCT02292706</DOCNO>
	<brief_summary>This Registry enroll cirrhotic participant without decompensated liver disease achieve sustained virologic response ( SVR ) receive sofosbuvir ( SOF ) -based regimen without interferon ( IFN ) participate Gilead-sponsored hepatitis C virus ( HCV ) study commercially select site . Once enrol , participant follow 5 year .</brief_summary>
	<brief_title>A Registry Participants With Cirrhosis Who Achieve Sustained Virologic Response Following Treatment With Sofosbuvir-Based Regimen Without Interferon Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing able provide write informed consent Have either previously participate Gileadsponsored HCV study receive sofosbuvircontaining regimen without interferon OR preselected site , receive alloral SOFbased regimen outside clinical study . These individual must documentation regimen , start end treatment date ( month year ) , achieve SVR12 . Have achieve SVR either Gileadsponsored study , define treatment protocol OR individual enroll receive alloral SOFbased regimen outside clinical study , SVR define HCV RNA &lt; LLOQ approximately 12 week follow last dose treatment . Have liver cirrhosis , define treatment protocol , liver transplant receive SOFcontaining regimen OR individual enroll receive alloral SOFbased regimen outside clinical study , cirrhosis confirm prior initiation HCV treatment . Individuals plan initiate new course HCV therapy , include approve product investigational agent , course Registry History clinicallysignificant illness major medical disorder may interfere followup , assessment , compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HCV Cirrhosis registry</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>